Literature DB >> 26829028

The Long Noncoding RNA SPRIGHTLY Regulates Cell Proliferation in Primary Human Melanocytes.

Wei Zhao1, Joseph Mazar1, Bongyong Lee1, Junko Sawada1, Jian-Liang Li1, John Shelley1, Subramaniam Govindarajan1, Dwight Towler1, John S Mattick2, Masanobu Komatsu1, Marcel E Dinger2, Ranjan J Perera3.   

Abstract

The long noncoding RNA SPRIGHTLY (formerly SPRY4-IT1), which lies within the intronic region of the SPRY4 gene, is up-regulated in human melanoma cells compared to melanocytes. SPRIGHTLY regulates a number of cancer hallmarks, including proliferation, motility, and apoptosis. To better understand its oncogenic role, SPRIGHTLY was stably transfected into human melanocytes, which resulted in increased cellular proliferation, colony formation, invasion, and development of a multinucleated dendritic-like phenotype. RNA sequencing and mass spectrometric analysis of SPRIGHTLY-expressing cells revealed changes in the expression of genes involved in cell proliferation, apoptosis, chromosome organization, regulation of DNA damage responses, and cell cycle. The proliferation marker Ki67, minichromosome maintenance genes 2-5, antiapoptotic gene X-linked inhibitor of apoptosis, and baculoviral IAP repeat-containing 7 were all up-regulated in SPRIGHTLY-expressing melanocytes, whereas the proapoptotic tumor suppressor gene DPPIV/CD26 was down-regulated, followed by an increase in extracellular signal-regulated kinase 1/2 phosphorylation, suggesting an increase in mitogen-activated protein kinase activity. Because down-regulation of DPPIV is known to be associated with malignant transformation in melanocytes, SPRIGHTLY-mediated DPPIV down-regulation may play an important role in melanoma pathobiology. Together, these findings provide important insights into how SPRIGHTLY regulates cell proliferation and anchorage-independent colony formation in primary human melanocytes.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26829028      PMCID: PMC4857189          DOI: 10.1016/j.jid.2016.01.018

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  46 in total

1.  Cyclin-dependent kinases prevent DNA re-replication through multiple mechanisms.

Authors:  V Q Nguyen; C Co; J J Li
Journal:  Nature       Date:  2001-06-28       Impact factor: 49.962

Review 2.  Eukaryotic MCM proteins: beyond replication initiation.

Authors:  Susan L Forsburg
Journal:  Microbiol Mol Biol Rev       Date:  2004-03       Impact factor: 11.056

3.  Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells.

Authors:  B Bauvois; M Djavaheri-Mergny; D Rouillard; J Dumont; J Wietzerbin
Journal:  Oncogene       Date:  2000-01-13       Impact factor: 9.867

4.  Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells.

Authors:  C L Pethiyagoda; D R Welch; T P Fleming
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Dipeptidyl peptidase IV (CD26) activity in the hematopoietic system: differences between the membrane-anchored and the released enzyme activity.

Authors:  D A Pereira; L Gomes; M C El-Cheikh; R Borojevic
Journal:  Braz J Med Biol Res       Date:  2003-04-22       Impact factor: 2.590

6.  Rac1 mediates dendrite formation in response to melanocyte stimulating hormone and ultraviolet light in a murine melanoma model.

Authors:  G A Scott; L Cassidy
Journal:  J Invest Dermatol       Date:  1998-08       Impact factor: 8.551

Review 7.  CD26/dipeptidyl peptidase IV and its role in cancer.

Authors:  B Pro; N H Dang
Journal:  Histol Histopathol       Date:  2004-10       Impact factor: 2.303

8.  Expression of CD26/dipeptidyl-peptidase IV in benign and malignant pigment-cell lesions of the skin.

Authors:  J J Van den Oord
Journal:  Br J Dermatol       Date:  1998-04       Impact factor: 9.302

9.  Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells.

Authors:  Umadevi V Wesley; Shakuntala Tiwari; Alan N Houghton
Journal:  Int J Cancer       Date:  2004-05-10       Impact factor: 7.396

10.  A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase.

Authors:  M E Morrison; S Vijayasaradhi; D Engelstein; A P Albino; A N Houghton
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  18 in total

1.  Identification of Long Noncoding RNA by In Situ Hybridization Approaches.

Authors:  Mara Mancini; Anna Maria Lena; Eleonora Candi
Journal:  Methods Mol Biol       Date:  2020

2.  Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer.

Authors:  Dongmei Zhang; Gao Zhang; Xiaowen Hu; Lawrence Wu; Yi Feng; Sidan He; Youyou Zhang; Zhongyi Hu; Lu Yang; Tian Tian; Weiting Xu; Zhi Wei; Yiling Lu; Keith T Flaherty; Xiaomin Zhong; Gordon B Mills; Phyllis A Gimotty; Xiaowei Xu; Meenhard Herlyn; Lin Zhang
Journal:  Cancer Res       Date:  2017-05-04       Impact factor: 12.701

3.  Long Non-Coding RNA SPRY4-IT1 Can Predict Unfavorable Prognosis and Lymph Node Metastasis: a Meta-Analysis.

Authors:  Nandi Li; Qian Tan; Wei Jing; Ping Luo; Jiancheng Tu
Journal:  Pathol Oncol Res       Date:  2017-01-04       Impact factor: 3.201

Review 4.  The long non-coding RNA SPRY4-IT1: An emerging player in tumorigenesis and osteosarcoma.

Authors:  Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2018-02-27       Impact factor: 6.831

5.  TUG1, SPRY4-IT1, and HULC as valuable prognostic biomarkers of survival in cancer: A PRISMA-compliant meta-analysis.

Authors:  Yucheng Zhong; Zhicong Chen; Shuyuan Guo; Xinhui Liao; Haibiao Xie; Yien Zheng; Bin Cai; Peixian Huang; Yuhan Liu; Qun Zhou; Yuchen Liu; Weiren Huang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

Review 6.  Long non-coding RNAs in cutaneous melanoma: clinical perspectives.

Authors:  Eva Hulstaert; Lieve Brochez; Pieter-Jan Volders; Jo Vandesompele; Pieter Mestdagh
Journal:  Oncotarget       Date:  2017-06-27

Review 7.  Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.

Authors:  Georg Richtig; Barbara Ehall; Erika Richtig; Ariane Aigelsreiter; Tony Gutschner; Martin Pichler
Journal:  Int J Mol Sci       Date:  2017-03-28       Impact factor: 5.923

8.  LncRNA GAS5 is a critical regulator of metastasis phenotype of melanoma cells and inhibits tumor growth in vivo.

Authors:  Long Chen; Huixin Yang; Yanbin Xiao; Xiaoxia Tang; Yuqian Li; Qiaoqiao Han; Junping Fu; Yuye Yang; Yuechun Zhu
Journal:  Onco Targets Ther       Date:  2016-07-04       Impact factor: 4.147

Review 9.  Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma.

Authors:  Allison L Isola; Kevinn Eddy; Suzie Chen
Journal:  Cancers (Basel)       Date:  2016-12-09       Impact factor: 6.639

10.  DPP4/CD26 overexpression in urothelial carcinoma confers an independent prognostic impact and correlates with intrinsic biological aggressiveness.

Authors:  Peir-In Liang; Bi-Wen Yeh; Wei-Ming Li; Ti-Chun Chan; I-Wei Chang; Chun-Nung Huang; Ching-Chia Li; Hung-Lung Ke; Hsin-Chih Yeh; Wen-Jeng Wu; Chien-Feng Li
Journal:  Oncotarget       Date:  2017-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.